A carregar...
IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
Despite the great impact on long-term survival of some cancer patients, the immune checkpoint blockade (ICB) therapy is limited by its low response rates for most cancers. There is a pressing need for novel combination immunotherapies that overcome the resistance to current ICB therapies. Cytokines...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7174717/ https://ncbi.nlm.nih.gov/pubmed/32351508 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00634 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|